JP2015521647A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521647A5
JP2015521647A5 JP2015519085A JP2015519085A JP2015521647A5 JP 2015521647 A5 JP2015521647 A5 JP 2015521647A5 JP 2015519085 A JP2015519085 A JP 2015519085A JP 2015519085 A JP2015519085 A JP 2015519085A JP 2015521647 A5 JP2015521647 A5 JP 2015521647A5
Authority
JP
Japan
Prior art keywords
nalmefene
pharmaceutical composition
composition according
day
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015519085A
Other languages
English (en)
Japanese (ja)
Other versions
JP6258933B2 (ja
JP2015521647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/063461 external-priority patent/WO2014001427A1/en
Publication of JP2015521647A publication Critical patent/JP2015521647A/ja
Publication of JP2015521647A5 publication Critical patent/JP2015521647A5/ja
Application granted granted Critical
Publication of JP6258933B2 publication Critical patent/JP6258933B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015519085A 2012-06-27 2013-06-27 特定の標的集団におけるアルコール消費を低減するためのナルメフェン Active JP6258933B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US61/664,804 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US61/721,539 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US61/736,740 2012-12-13
US201361788810P 2013-03-15 2013-03-15
US61/788,810 2013-03-15
PCT/EP2013/063461 WO2014001427A1 (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017182608A Division JP2018039810A (ja) 2012-06-27 2017-09-22 特定の標的集団におけるアルコール消費を低減するためのナルメフェン

Publications (3)

Publication Number Publication Date
JP2015521647A JP2015521647A (ja) 2015-07-30
JP2015521647A5 true JP2015521647A5 (enExample) 2017-02-09
JP6258933B2 JP6258933B2 (ja) 2018-01-10

Family

ID=48703496

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015519085A Active JP6258933B2 (ja) 2012-06-27 2013-06-27 特定の標的集団におけるアルコール消費を低減するためのナルメフェン
JP2017182608A Withdrawn JP2018039810A (ja) 2012-06-27 2017-09-22 特定の標的集団におけるアルコール消費を低減するためのナルメフェン
JP2019083718A Active JP6857684B2 (ja) 2012-06-27 2019-04-25 特定の標的集団におけるアルコール消費を低減するためのナルメフェン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017182608A Withdrawn JP2018039810A (ja) 2012-06-27 2017-09-22 特定の標的集団におけるアルコール消費を低減するためのナルメフェン
JP2019083718A Active JP6857684B2 (ja) 2012-06-27 2019-04-25 特定の標的集団におけるアルコール消費を低減するためのナルメフェン

Country Status (35)

Country Link
US (4) US20140005217A1 (enExample)
EP (5) EP3138564B1 (enExample)
JP (3) JP6258933B2 (enExample)
KR (1) KR20150023396A (enExample)
CN (1) CN104411313A (enExample)
AU (1) AU2013283281B2 (enExample)
BR (1) BR112014032555A2 (enExample)
CA (1) CA2874703C (enExample)
CL (1) CL2014003484A1 (enExample)
CO (1) CO7160087A2 (enExample)
CY (3) CY1118579T1 (enExample)
DK (3) DK3345604T3 (enExample)
EA (1) EA029908B1 (enExample)
ES (4) ES2609122T3 (enExample)
FI (1) FI3345604T3 (enExample)
HK (1) HK1255683A1 (enExample)
HR (4) HRP20250329T1 (enExample)
HU (4) HUE070621T2 (enExample)
IL (1) IL236035B (enExample)
LT (3) LT3138564T (enExample)
ME (2) ME02587B (enExample)
MX (1) MX371373B (enExample)
MY (1) MY166914A (enExample)
NZ (1) NZ702191A (enExample)
PH (1) PH12014502798A1 (enExample)
PL (4) PL3345604T3 (enExample)
PT (3) PT2866808T (enExample)
RS (2) RS55456B1 (enExample)
RU (1) RU2665373C2 (enExample)
SG (1) SG11201408704WA (enExample)
SI (3) SI2866808T1 (enExample)
SM (3) SMT201800164T1 (enExample)
UA (1) UA114199C2 (enExample)
WO (1) WO2014001427A1 (enExample)
ZA (1) ZA201409525B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
AU2015250611A1 (en) 2014-04-22 2016-11-24 H. Lundbeck A/S Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
WO2003015783A1 (en) * 2001-08-14 2003-02-27 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
CN102459276B (zh) 2009-05-25 2016-09-21 H.隆德贝克有限公司 从纳曲酮制备盐酸纳美芬
CA2815093C (en) 2010-11-05 2019-08-06 H. Lundbeck A/S Method for the manufacturing of naltrexone
JP5738470B2 (ja) 2011-03-31 2015-06-24 イムネクス ファーマ イラチュ サナイ ヴェ ティジャレット ア.シェ.Imuneks Farma Ilac Sanayi Ve Ticaret A.S. オピオイド拮抗体組成物、および強皮症の治療のためのその使用
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2013529665A5 (enExample)
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2009525343A5 (enExample)
JP2009280621A5 (enExample)
NZ620879A (en) A novel formulation of indomethacin
NZ714963A (en) Compositions and methods for treating anemia
JP2012193216A5 (enExample)
JP2012502047A5 (enExample)
JP2015521647A5 (enExample)
SI2889033T1 (en) Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
ME02474B (me) Terapijski režimi
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2018039810A5 (enExample)
JP2020500864A5 (enExample)
JP2013523628A5 (enExample)
JP2016505050A5 (enExample)
RU2014151156A (ru) Налмефен для уменьшения потребления алкоголя у конкретных целевых популяций
JP2016537364A5 (enExample)
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
JP2011500819A5 (enExample)
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.